About The Center for Cancer Genomics (CCG)
Recognizing the power of genomics, the National Cancer Institute (NCI) established the Center for Cancer Genomics (CCG) to develop and apply genome science to better diagnose and treat cancer patients. NCI is supporting research to identify the genetic drivers of cancer, to advance adoption of precise tumor diagnosis and treatment, and to prepare patients and their doctors for the changes in medical care influenced by genomics. Throughout these efforts, NCI protects patients’ privacy without hindering treatment or research.
CCG promotes opportunities to work with other agencies and community physicians to usher in a modern era of diagnosis, treatment, and prevention based on the study of genomes, gene expression, proteomics, and the use of other technologies. Currently, NCI is working with the cancer research community to ask:
- What are the key scientific opportunities?
- What is the best way to expedite discoveries to the clinic?
- Where are the bottlenecks in discovery, trial design, and standard of care?
- How can clinicians and scientists best exploit the sequencing of tumors in clinical practice to drive further discovery?
CCG unifies NCI’s activities in cancer genomics. Support begins with basic cancer genomics research, advances to technology to improve data accessibility, and continues through clinical translation to targeted and molecularly-informed treatment. CCG aims to synthesize research in different fields of cancer genomics – structural, functional and computational – with the goal of improving patient outcomes.
The Office of Cancer Genomics and The Cancer Genome Atlas Program Office are components of CCG.
OCG aims to improve prevention, early detection, diagnosis, and treatment of cancers by enhancing the understanding of the molecular mechanisms of different cancers, advancing genome science and technology development, and accelerating the translation of molecular findings into the clinic.
The CCG Programs Office
Overseeing the genome characterization pipeline, the office partners with clinical trials and community oncology groups to collect tissue samples and clinical data, applies large-scale characterization technologies, performs integrative, cross-platform analyses on the resulting data, and through the Genomic Data Commons, shares the data with the research community and facilitates further analyses.